A high risk group of patients with follicular lymphoma may benefit from a novel drug combination, a new study has found.
Follicular lymphoma, a B cell lymphoma, is an incurable form of non-Hodgkin lymphoma that is diagnosed each year in 120,000 people worldwide. Follicular lymphoma is characterized by slow and relentless tumor growth with inevitable relapses despite intense chemotherapy. Follicular lymphomas are driven by mutations that activate the BCL2 protein, which prevents cancer cells from dying, but additional genetic changes are also required. These could include mutations resulting in loss of cell cycle control, which is a hallmark of cancer and has a well-established role in aggressive B cell malignancies.
AdvertisementTo find out more, Hans-Guido Wendel and colleagues from Memorial Sloan-Kettering Cancer Center in New York analyzed genomic data from two large groups of slow-growing follicular lymphomas. The team identified a pattern of linked genetic mutations mainly in genes expressing cyclin-dependent kinases (CDKs), which impair the tumor-suppressing retinoblastoma (RB) pathway in nearly 50 percent of follicular lymphomas. The pathogenic role of these mutations was also confirmed in vivo in a mouse model of follicular lymphoma. Increased CDK4 activity is readily measured in tumor samples, and Wendel and colleagues show that a combination therapy of CDK4 and BCL2 inhibitors is safe and effective against available mouse models of follicular lymphoma.
About The Journal of Experimental Medicine
The Journal of Experimental Medicine (JEM) is published by The Rockefeller University Press. All editorial decisions on manuscripts submitted are made by active scientists in conjunction with our in-house scientific editors. JEM content is posted to PubMed Central, where it is available to the public for free six months after publication. Authors retain copyright of their published works and third parties may reuse the content for non-commercial purposes under a creative commons license.